LInezolid Monitoring to MInimise Toxicity (LIMMIT1): a multicentre retrospective review of patients receiving linezolid therapy and the impact of therapeutic drug monitoring.
Cindy LAU,Deborah MARRIOTT,Jessica BUI,Melanie FIGTREE,Michael GOULD,Adriana CHUBATY,Yuen SU,Suman ADHIKARI,Pam KONECNY,Kristi KOZIEROWSKI,Taylor HOLLAND,Eliza MILLIKEN,Ayesha AKRAM,Alexander MCNAMARA,Yihui SUN,Sebastiaan VAN HAL,Asad E PATANWALA,Aryan SHAHABI-SIRJANI,Timothy GRAY,Chin Yen YEO,Angela NETLUCH,Stephanie HALENA,Marcelle APPAY,Rozanna ALAMEDDINE,Fiona YIN,Quoc NGUYEN,Mei-Yi SO,Indy SANDARADURA,Hannah Yejin KIM,Semun GALIMAM,Nicole CERRUTO,Tony LAI,Timothy GILBEY,Kathryn DAVESON,Stephanie E REUTER,Jonathan PENM,Jan-Willem ALFFENAAR
DOI: https://doi.org/10.1016/j.ijantimicag.2023.106783
IF: 15.441
2023-03-15
International Journal of Antimicrobial Agents
Abstract:Background Linezolid is a broad-spectrum antimicrobial but toxicity limits it use. This study aimed to evaluate linezolid toxicity in a large multicentre cohort. Secondary objectives were to identify factors contributing to toxicity, including the impact of therapeutic drug monitoring (TDM). Methods Patients administered linezolid between January 2017 and December 2019 were reviewed retrospectively. Data was collected on patient characteristics, linezolid therapy and outcomes. Descriptive statistics were performed on all patients, and statistical comparisons were undertaken between patients who did and did not experience linezolid toxicity. A multivariable logistic regression model was constructed to identify any covariates correlated with toxicity. Results Linezolid was administered to 1,050 patients. Of these, 381 patients did not meet the inclusion criteria, and 47 patients were excluded as therapy ceased for non-toxicity reasons. There were 105/622 (16.9%) patients assessed to have linezolid toxicity. Those who experienced toxicity displayed a higher baseline creatinine (96.5μmol/L vs 79μmol/L, p=0.025), lower baseline platelet count (225 × 10 9 /L vs 278.5 × 10 9 /L, p=0.002), and received a longer course (median 21 vs 14 days, p 28 days was no longer significantly associated with toxicity. Conclusions This study confirmed linezolid treatment-limiting toxicity remains a problem, and suggests that TDM-guided dose optimisation may reduce the risk of toxicity and facilitate prolonged courses beyond 28 days.
pharmacology & pharmacy,infectious diseases,microbiology